Antisense Therapeutics Ltd
ASX:ANP
Antisense Therapeutics Ltd
ASX:ANP
Price:
0.084
AUD
1.2%
Market Closed
Market Cap:
AU$75.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Antisense Therapeutics Ltd
ASX:ANP
|
AU |
|
Damon Technology Group Co Ltd
SSE:688360
|
CN |
|
J
|
Jiangxi Copper Co Ltd
XBER:JIX
|
CN |
|
W
|
Wallbox NV
NYSE:WBX
|
ES |
|
E
|
Europen Endustri Insaat Sanayi ve Ticaret AS
IST:EUREN.E
|
TR |
|
Lang & Schwarz AG
XETRA:LUS1
|
DE |
|
Websol Energy System Ltd
NSE:WEBELSOLAR
|
IN |
Balance Sheet
Balance Sheet Decomposition
Antisense Therapeutics Ltd
Antisense Therapeutics Ltd
Balance Sheet Decomposition is not available for
Antisense Therapeutics Ltd
Antisense Therapeutics Ltd
Balance Sheet
Antisense Therapeutics Ltd
Antisense Therapeutics Ltd
Currency: AUD
| Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | Jun-2022 | Jun-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
1
|
7
|
5
|
2
|
2
|
3
|
4
|
6
|
1
|
0
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Cash Equivalents |
1
|
7
|
5
|
2
|
2
|
3
|
4
|
6
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
11
|
|
| Total Receivables |
1
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
|
| Accounts Receivables |
0
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
2
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
1
|
0
|
|
| Total Current Assets |
3
|
8
|
5
|
3
|
5
|
4
|
5
|
7
|
22
|
13
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
3
N/A
|
8
+189%
|
5
-31%
|
3
-52%
|
5
+89%
|
4
-23%
|
5
+45%
|
7
+31%
|
22
+220%
|
13
-43%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Total Current Liabilities |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
3
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
+4%
|
1
+26%
|
1
-9%
|
1
-15%
|
1
+53%
|
1
-8%
|
1
+55%
|
1
+2%
|
3
+121%
|
|
| Equity | |||||||||||
| Common Stock |
52
|
57
|
57
|
58
|
62
|
64
|
69
|
77
|
98
|
98
|
|
| Retained Earnings |
50
|
50
|
52
|
56
|
58
|
61
|
65
|
71
|
77
|
88
|
|
| Total Equity |
2
N/A
|
7
+239%
|
5
-35%
|
2
-60%
|
4
+128%
|
3
-33%
|
5
+61%
|
6
+26%
|
21
+269%
|
10
-53%
|
|
| Total Liabilities & Equity |
3
N/A
|
8
+189%
|
5
-31%
|
3
-52%
|
5
+89%
|
4
-23%
|
5
+45%
|
7
+31%
|
22
+220%
|
13
-43%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
160
|
196
|
179
|
180
|
372
|
420
|
489
|
574
|
669
|
669
|
|
Switch to:
Switch to:
See Also
Discover More
